[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microcirculatory-status\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microcirculatory-status":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100631250","coronoary-microcirculation-analysis-network-100631250",false,"NCT07498231","COronoary Microcirculation Analysis NETwork","Assessment of Risk Factors for Coronary Circulatory and Microcirculatory Disorders, Comparison of Invasive and Non-Invasive Diagnostic Methods, and Evaluation of the Impact of Individualized Pharmacotherapy Optimization on Patients' Quality of Life","COMA-NET","Inclusion Criteria:\n\na. Chronic coronary syndrome c. Anginal symptoms \\> CCS class I or angina equivalent d. Myocardial ischemia confirmed by non-invasive testing e. Provision of informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Angiographically significant coronary artery stenosis or FFR \\\u003C 0.8\n2. Renal insufficiency with eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²\n3. Left ventricular ejection fraction \\\u003C 40%\n4. Hypertrophic cardiomyopathy\n5. Acute coronary syndrome within \\\u003C 90 days\n6. Percutaneous coronary intervention (PCI) within \\\u003C 90 days\n7. Previous coronary artery bypass grafting (CABG)\n8. Anemia \\\u003C 10 g\u002FdL or thrombocytopenia \\\u003C 100,000\u002FµL\n9. Intraventricular conduction disturbances preventing ST-T segment assessment\n10. Severe concomitant valvular heart disease\n11. Active malignancy\n12. Type 1 diabetes mellitus\n13. Coronary artery anatomical abnormalities precluding assessment using PressureWire X (myocardial bridge causing \\> 50% luminal narrowing of the investigated vessel, severe coronary tortuosity, inability to properly cannulate coronary ostia)\n14. Pregnancy\n15. Heart failure ≥ NYHA class III\n16. Asthma or COPD with severe irreversible airflow obstruction\n17. Atrial fibrillation\n18. Second- or third-degree atrioventricular block without pacemaker implantation (IPG)\n19. Manifest pre-excitation on ECG or history of AVRT episodes without prior ablation of the accessory pathway","ALL","18 Years","75 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, parallel-group clinical trial designed to determine whether endotype-guided pharmacotherapy is superior to standard care in improving quality of life in patients with ischemia with non-obstructive coronary arteries. Approximately 180-190 participants with objective ischemia will be randomized to either the control or the intervention group.\n\nPharmacotherapy based on the endotype established during intracoronary assessment will be introduced in the intervention arm of the study. The primary endpoint is the change in the Seattle Angina Questionnaire (SAQ) score from baseline to 3 months. Secondary endpoints include the diagnostic accuracy of transthoracic echocardiographic coronary flow velocity reserve (CFVR), the incidence of adverse events, associations between biomarkers and coronary microvascular dysfunction (CMD), and the identification of risk factors for specific CMD endotypes.\n\nParticipants will undergo invasive functional evaluation of the coronary microcirculation, measurement of echocardiographic CFVR, and analysis of selected circulating biomarkers. The study cohort will be followed up at three and six months and will include reassessment of quality of life (Seattle Angina Questionnaire, EuroQol 5-Dimensions 5-Level questionnaire, 12-item Short Form Health Survey), anxiety (Generalized Anxiety Disorder-7 score), and functional status (6-minute walk test).\n\nThe study began in October 2025. Primary completion is anticipated in October 2027, and the overall study completion date is expected in March 2028.",[28,29,30,31,32,33,34],"Coronary Artery Disease","Microcirculation Resistance","Microcirculation; Biomarkers; Myocardial Ischemia","Microcirculatory Dysfunction","Microcirculatory Status","Echocardiography","Doppler Echocardiography",[36,37,38,39,40,41,42],"coma.net","coma-net","coronary microcirculation","ANOCA","INOCA","angina with non-obstructive coronary arteries","ischemia with non-obstructive coronary arteries","RECRUITING","2026-04-02",{"date":46,"type":47},"2026-04-08","ACTUAL",{"date":49,"type":47},"2025-10-10",{"date":51,"type":22},"2028-03",{"name":53,"class":54},"Medical University of Bialystok","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":75,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":55},"100623641","submental-tissue-oxygenation-and-arterial-lactate-in-major-surgery-100623641","NCT07399275","Submental Tissue Oxygenation and Arterial Lactate in Major Surgery","Relationship Between Submental Tissue Oxygenation, Microvascular Reactivity, and Arterial Lactate During Major Surgical Procedures","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Scheduled for major surgical procedures under general anesthesia\n* Major surgery defined as procedures associated with a risk of significant blood loss and\u002For impaired tissue perfusion, requiring invasive arterial blood pressure monitoring and hourly arterial blood gas analysis\n* Planned intraoperative arterial catheter placement as part of routine clinical care\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Refusal or inability to provide informed consent\n* Absence of invasive arterial blood pressure monitoring\n* Known pregnancy\n* Severe peripheral vascular disease affecting upper extremities\n* Anatomical abnormalities or skin conditions preventing placement of NIRS sensors on the submental or thenar regions\n* Emergency surgery requiring immediate intervention\n* Preoperative severe metabolic acidosis (arterial pH \\\u003C 7.20)",true,{"count":65,"type":22},150,"OBSERVATIONAL","During major surgical procedures performed under general anesthesia, changes in blood flow and oxygen delivery to tissues may occur due to blood loss, hemodynamic fluctuations, and anesthesia-related physiological effects. These changes can lead to impaired tissue perfusion, which is commonly reflected by increased arterial lactate levels. However, lactate measurements are intermittent and may not detect early perfusion abnormalities.\n\nThis prospective observational study aims to investigate the relationship between submental tissue oxygenation measured by near-infrared spectroscopy (NIRS), microvascular reactivity assessed by the vascular occlusion test, and arterial lactate levels during major surgery. Adult patients undergoing major abdominal, neurosurgical, or orthopedic procedures will be monitored intraoperatively using non-invasive NIRS techniques, while arterial blood gas analyses will be performed as part of routine clinical care.\n\nThe study does not involve any changes to standard anesthesia or surgical management. All treatments and clinical decisions will be made by the responsible care team according to routine practice. By evaluating non-invasive indicators of tissue oxygenation and microvascular function, this study aims to improve the understanding of early intraoperative tissue perfusion changes and their association with metabolic markers.",[31,69,32,70,71,72,73,74],"Tissue Hypoperfusion","Microvascular Circulation","Near Infrared Spectroscopy","Vascular Occlusion Test","Lactate Blood Increase","Major Surgery",[76,77,78,79,80,81],"tissue hypoperfusion","microvascular circulation","Near infrared spectroscopy","vascular occlusion","lactate blood increase","Major surgery","NOT_YET_RECRUITING","2026-02-03",{"date":85,"type":47},"2026-02-10",{"date":87,"type":22},"2026-02-15",{"date":89,"type":22},"2027-02-15",{"name":91,"class":92},"Bursa Sevket Yilmaz Training and Research Hospital","OTHER_GOV",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":101,"targetDuration":103,"studyType":66,"phases":4,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":55},"100561290","inoca-na-a-local-prospective-registry-100561290","NCT06588244","INOCA-NA a Local Prospective Registry","Ischemia in Patients with Non- Obstructive Disease (INOCA) - a Local Prospective Registry (INOCA-Naples)","INOCA-NA","Inclusion Criteria:\n\n* Clinical presentation of chronic ischemic heart dis- ease (IHD), requiring coronary angiography for the diagnosis;\n* Absence of obstructive coronary artery disease (CAD) at coronary angiography;\n* Age \\> 18 years.\n* Ability to provide a valid informed consent to the study procedure at the time of baseline evaluation;\n\nExclusion Criteria:\n\nClinical presentation of acute coronary syndrome (ACS) or cardiogenic shock;\n\n* Presence of obstructive CAD with at least 1 significant coronary artery stenosis, defined as diameterstenosis \\>50% and FFR ≤0.80 (or iFR\u002FRFR ≤0.89);\n* Previous coronary artery bypass grafting (CABG);\n* Left ventricular systolic dysfunction, defined as ejection fraction (EF) \\<40%;\n* Severe valvular heart disease;\n* Pregnant or breastfeeding women\n* Known hypersensitivity or contraindication to any of the drugs used for coronary physiology testing (adenosine, nitrates, acetylcholine)\n* Inability or unwillingness to provide a valid in- formed consent to the study procedure at the time of baseline evaluation.",{"count":102,"type":22},250,"1 Year","The present study has the following objectives:\n\n1. To investigate the prevalence of INOCA in patients referring for a clinically indicated coronary angiography (CA) c\u002Fo Division of Cardiology - Federico II University Hospital;\n2. To stratify in INOCA endotypes patients according to the presence or absence of alternative (i.e. non obstructive CAD) causes of myocardial ischemia detected during CA clinically indicated through physiology tests;\n3. to implement a stratified therapy in these patients considering the different INOCA endotypes and evaluate the impact on angina class and quality of life as well as cardiac hospitalization and coronary revascularization during 5 year follow up",[106,107,32,108],"Ischemia, Myocardial","Non-Obstructive Coronary Atherosclerosis","Coronary Microvascular Dysfunction (CMD)",[40,110,111],"CMD","VSA","2025-03-12",{"date":114,"type":47},"2025-03-17",{"date":116,"type":47},"2024-09-19",{"date":118,"type":22},"2027-09-01",{"name":120,"class":54},"Federico II University"]